Thrombolysis will continue to be the mainstay for acute stroke treatment

Thrombolysis will continue to be the mainstay for acute stroke treatment

Thrombolysis will continue to be the mainstay for acute stroke treatment, despite the recent revolution in neurointerventional clot retrieval. However, as there are ongoing limitations of thrombolysis of bleeding risk and reduced efficacy in large clots – what possible therapeutic advancements can complement or act as an adjuvant to thrombolysis? Neurointervention – effective, but limited […]

Read More

January 2nd, 2017

Regulatory timelines in the Asia-Pacific

An at-a-glance round-up of the arrangements for clinical trial applications in 10 countries in the region. Australia Australia is unique in that its Human Research Ethics Committees (HRECs) have responsibility for the oversight and ongoing monitoring of trials, including reviews and approvals. The first step is submission of the clinical trial to the HREC for […]

Read More

December 30th, 2016

The Changing Role of the CRA in an RBM World

Approximately a third of clinical trials conducted utilize some elements of Risk Based Monitoring (RBM), with this figure expected to increase. Site monitoring has been identified as one of the largest components of clinical trial expenditure. With the change in the way that site monitoring is performed, the role of the Clinical Research Associate (CRA) […]

Read More

December 28th, 2016

China-Australia Free Trade Agreement – The Healthcare Opportunity

China is Australia’s largest trading partner – worth $8.8 billion in 2014-2015. China and Australia are also growing partners in science and research and this is an important area for growth in bilateral relations. China is and has been Australia’s key focus for science and research collaboration efforts; generating advances in medical research, biodiversity, net […]

Read More

December 26th, 2016

Preventing cardiovascular disease through a simple text message

The World Health Organization states that cardiovascular disease (CVD) has been the number one global cause of death; with an estimation of 17.5 million people dying from CVD in 20121, representing 31% of all global deaths. CVD has been and is currently the major cause of death in Australia2 accounting for over 43,600 deaths in […]

Read More

December 23rd, 2016

Steadying confidence for clinical trials in India

For over 30 years, India has been conducting global clinical trials. With over 500 sites and over a billion people, India was a key destination for clinical trials for its vast treatment naïve clinical population. However, the environment has fluctuated throughout recent years, as The Central Drugs Standard Control Organization (CDSCO), India’s regulatory agency for […]

Read More

December 21st, 2016

SMARTHealth – A study on e-health in rural communities

Health systems in low and middle income countries continue to face considerable challenges in providing high-quality, affordable and universally accessible care – this is primarily evident in rural areas. As of 2014, approximately 876.1 million people live in rural areas within India with poor access to primary healthcare. This amounts to more than two-thirds of […]

Read More

December 19th, 2016
Part III China

Part III: China’s Future in Global Clinical Research

Active international collaboration has facilitated the rise of the Asia-Pacific region in global clinical research. In the first two parts of this blog series, we’ve discussed how Japan and South Korea – whose clinical research environments vary significantly from each other – share many common interests in their pursuit for advancing clinical R&D. The open […]

Read More

December 7th, 2016
Part II Insights on CT environment – Sth Korea

Part II: Insights on the Clinical Trial Landscape of South Korea

Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia-Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable […]

Read More

December 5th, 2016

The Scientific Leadership Model an Innovative Approach to Clinical Trial Leadership, Design and Delivery

In this webinar, featured speakers, Professor Craig Anderson and Emma Field define and discuss the emergence of the Scientific Leadership Model as an innovative service addition to a clinical trials design and delivery in Asia. This presentation will also showcase the results and success of one of the largest obstructive sleep apnea medical device trials […]

Read More

November 30th, 2016

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network